NAV

Beta-Hydroxyaspartic Acid

Identification

Generic Name
Beta-Hydroxyaspartic Acid
DrugBank Accession Number
DB03640
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 149.1021
Monoisotopic: 149.032422339
Chemical Formula
C4H7NO5
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UBeta-lactamase TEMNot AvailableSalmonella typhi
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aspartic acid and derivatives. These are compounds containing an aspartic acid or a derivative thereof resulting from reaction of aspartic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Aspartic acid and derivatives
Alternative Parents
L-alpha-amino acids / Short-chain hydroxy acids and derivatives / Beta hydroxy acids and derivatives / Monosaccharides / Fatty acids and conjugates / Dicarboxylic acids and derivatives / Alpha hydroxy acids and derivatives / Secondary alcohols / Amino acids / Carboxylic acids
show 5 more
Substituents
Alcohol / Aliphatic acyclic compound / Alpha-amino acid / Alpha-hydroxy acid / Amine / Amino acid / Aspartic acid or derivatives / Beta-hydroxy acid / Carbonyl group / Carboxylic acid
show 16 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
3-hydroxy-L-aspartic acid (CHEBI:17576)
Affected organisms
Not Available

Chemical Identifiers

UNII
GDV0MSK2SG
CAS number
Not Available
InChI Key
YYLQUHNPNCGKJQ-NHYDCYSISA-N
InChI
InChI=1S/C4H7NO5/c5-1(3(7)8)2(6)4(9)10/h1-2,6H,5H2,(H,7,8)(H,9,10)/t1-,2+/m0/s1
IUPAC Name
(2S,3R)-2-amino-3-hydroxybutanedioic acid
SMILES
N[C@@H]([C@@H](O)C(O)=O)C(O)=O

References

General References
Not Available
KEGG Compound
C03961
PubChem Compound
14463
PubChem Substance
46508333
ChemSpider
13809
BindingDB
50055467
ChEBI
17576
ChEMBL
CHEMBL3317781
ZINC
ZINC000000901877
PDBe Ligand
BH2
PDB Entries
1ccf / 2dde / 4pb5 / 6c0h / 6c0y

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility111.0 mg/mLALOGPS
logP-3.4ALOGPS
logP-4.4Chemaxon
logS-0.13ALOGPS
pKa (Strongest Acidic)2.57Chemaxon
pKa (Strongest Basic)9.08Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area120.85 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity27.87 m3·mol-1Chemaxon
Polarizability12.17 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.523
Blood Brain Barrier-0.6851
Caco-2 permeable-0.8778
P-glycoprotein substrateNon-substrate0.8316
P-glycoprotein inhibitor INon-inhibitor0.9657
P-glycoprotein inhibitor IINon-inhibitor0.9601
Renal organic cation transporterNon-inhibitor0.9708
CYP450 2C9 substrateNon-substrate0.8754
CYP450 2D6 substrateNon-substrate0.8784
CYP450 3A4 substrateNon-substrate0.7968
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9946
Ames testNon AMES toxic0.9356
CarcinogenicityNon-carcinogens0.801
BiodegradationReady biodegradable0.8991
Rat acute toxicity1.2497 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9941
hERG inhibition (predictor II)Non-inhibitor0.9795
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-052f-9100000000-af8204a8797562a5e1a8
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fer-9600000000-73b954b1d6cbca538b66
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-3900000000-6689a4ea8601ceb0a004
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-052r-9000000000-abac5b8d3c05bd643ad3
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0kmi-9300000000-2bd1ab7979f245ec71dd
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-ec05d231454ba29483a2
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-006x-9000000000-3735d0d06d0e7327d3fa
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-129.877262
predicted
DarkChem Lite v0.1.0
[M-H]-125.18875
predicted
DeepCCS 1.0 (2019)
[M+H]+129.648062
predicted
DarkChem Lite v0.1.0
[M+H]+127.58431
predicted
DeepCCS 1.0 (2019)
[M+Na]+129.440562
predicted
DarkChem Lite v0.1.0
[M+Na]+134.85728
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Beta-lactamase TEM
Kind
Protein
Organism
Salmonella typhi
Pharmacological action
Unknown
General Function
Beta-lactamase activity
Specific Function
TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalos...
Gene Name
bla
Uniprot ID
P62594
Uniprot Name
Beta-lactamase TEM
Molecular Weight
31514.865 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52